Per Malmström

4.1k citations
61 papers · 2.7k · h-index 27

Impact in

  • Cancer Research top 2%
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics
  • Oncology top 2%
    • HER2/EGFR in Cancer Research
    • Cancer Cells and Metastasis
    • Cancer Treatment and Pharmacology
    • Cancer-related Molecular Pathways

Papers in

  • Cancer Research 34
    • Breast Cancer Treatment Studies 30
    • Cancer Genomics and Diagnostics 3
  • Oncology 18
    • HER2/EGFR in Cancer Research 7
    • Cancer Treatment and Pharmacology 6
    • Cancer survivorship and care 5
    • Cancer-related Molecular Pathways 3
Co-authors
Mårten Fernö (32 shared papers)Pär‐Ola Bendahl (14 shared papers)Jorma Isola (3 shared papers)Sofia K. Gruvberger-Saal (4 shared papers)Jonas Bergh (11 shared papers)Lao H. Saal (3 shared papers)Åke Borg (3 shared papers)Dorthe Grabau (10 shared papers)
Journals
Journal of Clinical Oncology (10 papers)Acta Oncologica (5 papers)Breast Cancer Research and Treatment (5 papers)European Journal of Cancer (4 papers)The Breast (3 papers)
Partner nations
SwedenUnited StatesFinland

In The Last Decade

Per Malmström

61 papers receiving 2.6k citations

Peers

Per Malmström
Comparison fields: 5 of 102
  • Cancer Research 879
  • Oncology 931
  • Genetics 154
  • Pulmonary and Respiratory Medicine 368
  • Molecular Biology 837
Replace Melanie Royce with:
Melanie Royce United States
Florence Lerebours France
Thomas Bachelot France
E. McDermott Ireland
Alberto Bottini Italy
Ritu Roy United States
Mónica Arnedos France
G. Viale Italy
James R. Vasselli United States
Romano Demicheli Italy
Per Malmström relative to Melanie Royce United States Melanie Royce's profile →
Citations per field
00.5×1.6×
Melanie Royce · 1×
Citations per year

Countries citing papers authored by Per Malmström

Since Specialization
Citations

This map shows the geographic impact of Per Malmström's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Malmström with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Malmström more than expected).

Fields of papers citing papers by Per Malmström

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Malmström. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Malmström. The network helps show where Per Malmström may publish in the future.

Co-authors

The 25 scholars most cited alongside Per Malmström, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Per Malmström Line = papers co-authored together Per Malmström links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Proceedings of the National Academy of Sciences ·Lao H. Saal, Peter A. Johansson, Karolina Holm, Sofia K. Gruvberger-Saal, Qing‐Bai She, Matthew Maurer, Susan Koujak, Adolfo A. Ferrando, Per Malmström, Lorenzo Memeo, Jorma Isola, Pär‐Ola Bendahl, Neal Rosen, Hanina Hibshoosh, Markus Ringnér, Åke Borg, Ramon Parsons
2007404
2
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
The Lancet ·Jonas Bergh, Tom Wiklund, Björn Erikstein, Elisabet Lidbrink, Henrik Lindman, Per Malmström, Pirkko Kellokumpu‐Lehtinen, Nils‐Olof Bengtsson, Gustaf Söderlund, Gun Anker, Erik Wist, S. Ottosson, Eeva Salminen, Per Ljungman, Harald Holte, Jonas Nilsson, Carl Blomqvist, Nils Wilking
2000216
3
Topoisomerase IIα Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu–Amplified Breast Cancer: Scandinavian Breast Group Trial 9401
Journal of Clinical Oncology ·Minna Tanner, Jorma Isola, Tom Wiklund, Björn Erikstein, Pirkko Kellokumpu‐Lehtinen, Per Malmström, Nils Wilking, Jonas Nilsson, Jonas Bergh
2006193
4
Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma
Clinical Cancer Research ·Sofia K. Gruvberger-Saal, Pär‐Ola Bendahl, Lao H. Saal, Mervi Laakso, Cecilia Hegardt, P. Edén, Carsten Peterson, Per Malmström, Jorma Isola, Åke Borg, Mårten Fernö
2007155
5
Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes
Molecular Oncology ·Karolina Holm, Dorthe Grabau, Kristina Lövgren, S. Aradottir, Sofia K. Gruvberger-Saal, Jillian Howlin, Lao H. Saal, Stephen P. Ethier, Pär‐Ola Bendahl, Olle Stål, Per Malmström, Mårten Fernö, Lisa Rydén, Cecilia Hegardt, Åke Borg, Markus Ringnér
2012125
6
The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.
PubMed ·Johanna Sjöström, Carl Blomqvist, Kristina von Boguslawski, Nils‐Olof Bengtsson, Ingvil Mjaaland, Per Malmström, Björn Ostenstadt, Erik Wist, Vahur Valvere, Shinichi Takayama, John C. Reed, E Saksela
2002119
7
A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4
Cancer ·Magnhild Sandberg‐Wollheim, K Hougaard, Per Malmström, Lars-Göran Strömblad, Leif G. Salford, Harald Anderson, S Borgström, Arne Brun, S. Cronqvist
199197
8
Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial
Journal of Clinical Oncology ·Martin Sjöström, Dan Lundstedt, Linda Hartman, Erik Holmberg, Fredrika Killander, Anikó Kovács, Per Malmström, Emma Niméus, Elisabeth Werner Rönnerman, Mårten Fernö, Per Karlsson
201780
9
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
PubMed ·Johanna Sjöström, Carl Blomqvist, Päivi Heikkilä, Kristina von Boguslawski, Anne Räisänen‐Sokolowski, Nils Olof Bengtsson, Ingvil Mjaaland, Per Malmström, Björn Ostenstadt, Jonas Bergh, Erik Wist, Vahur Valvere, E Saksela
200074
10
The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer
Modern Pathology ·Marie Klintman, Pär‐Ola Bendahl, Dorthe Grabau, Kristina Lövgren, Per Malmström, Mårten Fernö
200973
11
Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment
OncoImmunology ·Christina Mertens, Javier Mora, Bilge Ören, Stephan Grein, Sofia Winslow, Klaus Scholich, Andreas Weigert, Per Malmström, Carina Forsare, Mårten Fernö, Tobias Schmid, Bernhard Brüne, Michaela Jung
201771
12
Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer
Breast Cancer Research and Treatment ·Martin Sjöström, Linda Hartman, Dorthe Grabau, Tommy� Fornander, Per Malmström, Bo Nordenskjöld, Dennis C. Sgroi, Lambert Skoog, Olle Stål, L.M. Fredrik Leeb-Lundberg, Mårten Fernö
201467
13
Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: A phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5)
European Journal of Cancer ·Marie Magnusson, Peter Höglund, Karin Johansson, Charlotta Jönsson, Fredrika Killander, Per Malmström, Anna Weddig, Elisabeth Kjellén
200961
14
Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer
Journal of Clinical Oncology ·Martin Sjöström, S. Laura Chang, Nick Fishbane, Elai Davicioni, Shuang G. Zhao, Linda Hartman, Erik Holmberg, Felix Y. Feng, Corey Speers, Lori J. Pierce, Per Malmström, Mårten Fernö, Per Karlsson
201959
15
Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013
Acta Oncologica ·Anna Ehinger, Per Malmström, Pär‐Ola Bendahl, C.W. Elston, Anna-Karin Falck, Carina Forsare, Dorthe Grabau, Lisa Rydén, Olle Stål, Mårten Fernö, (unknown)
201651
16
Exploring the two-gene ratio in breast cancer—independent roles for HOXB13 and IL17BR in prediction of clinical outcome
Breast Cancer Research and Treatment ·Piiha-Lotta Jerevall, Sara Brommesson, Carina Strand, Sofia K. Gruvberger-Saal, Per Malmström, Bo Nordenskjöld, Sten Wingren, Peter Söderkvist, Mårten Fernö, Olle Stål
200748
17
Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy
Breast Cancer Research ·Emma Niméus, Morten Krogh, Per Malmström, Carina Strand, Irma Fredriksson, Per Karlsson, Bo Nordenskjöld, Olle Stål, G Ostberg, Carsten Peterson, Mårten Fernö
200848
18
Claudin‐2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences
Molecular Oncology ·Siker Kimbung, Anikó Kovács, Pär‐Ola Bendahl, Per Malmström, Mårten Fernö, Thomas Hatschek, Ingrid Hedenfalk
201347
19
Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial
Journal of Clinical Oncology ·Anikó Kovács, Axel Stenmark Tullberg, Elisabeth Werner Rönnerman, Erik Holmberg, Linda Hartman, Martin Sjöström, Dan Lundstedt, Per Malmström, Mårten Fernö, Per Karlsson
201947
20
TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer
Acta Oncologica ·Kenneth Villman, Johanna Sjöström, Reino Heikkilä, Ragnar Hultborn, Per Malmström, Nils‐Olof Bengtsson, Martin Söderberg, E Saksela, Carl Blomqvist
200644

About Per Malmström

Per Malmström is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology and Pathology and Forensic Medicine, having authored 61 papers that have together received 2.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (30 papers), HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (6 papers), Breast Lesions and Carcinomas (5 papers), Cancer survivorship and care (5 papers), Cancer Genomics and Diagnostics (3 papers), Cancer-related cognitive impairment studies (3 papers) and Cancer-related Molecular Pathways (3 papers). The work is most often cited by research in Cancer Research (879 citations), Oncology (931 citations), Genetics (154 citations), Pulmonary and Respiratory Medicine (368 citations) and Molecular Biology (837 citations). Per Malmström has collaborated with scholars based in Sweden, United States and Finland. Frequent co-authors include Mårten Fernö, Pär‐Ola Bendahl, Jorma Isola, Sofia K. Gruvberger-Saal, Jonas Bergh, Lao H. Saal, Åke Borg, Dorthe Grabau, Martin Sjöström and Carl Blomqvist. Their work appears in journals such as Journal of Clinical Oncology, Acta Oncologica, Breast Cancer Research and Treatment, European Journal of Cancer and The Breast.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Melanie RoyceBreakdown of academic impact, for papers by Florence LereboursBreakdown of academic impact, for papers by Thomas BachelotBreakdown of academic impact, for papers by E. McDermottBreakdown of academic impact, for papers by Alberto BottiniBreakdown of academic impact, for papers by Ritu RoyBreakdown of academic impact, for papers by Mónica ArnedosBreakdown of academic impact, for papers by G. VialeBreakdown of academic impact, for papers by James R. VasselliBreakdown of academic impact, for papers by Romano Demicheli